Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon.

Tytuł:
Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon.
Autorzy:
Djontu JC; Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
Lloyd YM; John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, United States of America.
Megnekou R; Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
Seumko'o RMN; Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
Salanti A; Department of Immunology and Microbiology, Center for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark.; Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Taylor DW; John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, United States of America.
Leke RGF; The Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon.
Źródło:
PloS one [PLoS One] 2020 Aug 14; Vol. 15 (8), pp. e0237671. Date of Electronic Publication: 2020 Aug 14 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Antibodies, Protozoan/*immunology
Antigens, Protozoan/*immunology
Antimalarials/*therapeutic use
Malaria, Falciparum/*prevention & control
Pregnancy Complications, Parasitic/*prevention & control
Pyrimethamine/*therapeutic use
Sulfadoxine/*therapeutic use
Adult ; Antibodies, Protozoan/blood ; Cameroon/epidemiology ; Drug Combinations ; Female ; Humans ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Malaria/blood ; Malaria/epidemiology ; Malaria/immunology ; Malaria/prevention & control ; Malaria, Falciparum/blood ; Malaria, Falciparum/epidemiology ; Malaria, Falciparum/immunology ; Plasmodium falciparum/drug effects ; Plasmodium falciparum/immunology ; Pregnancy ; Pregnancy Complications, Parasitic/blood ; Pregnancy Complications, Parasitic/epidemiology ; Pregnancy Complications, Parasitic/immunology ; Young Adult
References:
Am J Trop Med Hyg. 2016 Mar;94(3):640-9. (PMID: 26711513)
PLoS One. 2014 Feb 04;9(2):e88173. (PMID: 24505415)
Infect Immun. 2018 Aug 22;86(9):. (PMID: 29986889)
J Immunol. 2010 Dec 15;185(12):7553-61. (PMID: 21078904)
Bull World Health Organ. 1983;61(6):1005-16. (PMID: 6370484)
Infect Immun. 2019 Jun 20;87(7):. (PMID: 30988054)
J Exp Med. 2004 Nov 1;200(9):1197-203. (PMID: 15520249)
PLoS One. 2012;7(6):e40049. (PMID: 22761948)
Lancet. 2004 Jan 24;363(9405):283-9. (PMID: 14751701)
Infect Immun. 2003 Nov;71(11):6620-3. (PMID: 14573685)
Malar J. 2014 Apr 30;13:162. (PMID: 24779545)
Science. 1996 Jun 7;272(5267):1502-4. (PMID: 8633247)
Mol Microbiol. 2003 Jul;49(1):179-91. (PMID: 12823820)
J Infect Dis. 2010 Jan 1;201(1):123-31. (PMID: 19954383)
EMBO Rep. 2005 Aug;6(8):775-81. (PMID: 16025132)
Bull Soc Pathol Exot. 2011 Oct;104(4):277-83. (PMID: 21818679)
Malar J. 2015 Dec 01;14:480. (PMID: 26626275)
Malar J. 2015 May 26;14:215. (PMID: 26006260)
Clin Vaccine Immunol. 2006 Dec;13(12):1307-13. (PMID: 17035513)
Open Forum Infect Dis. 2016 May 10;3(2):ofw092. (PMID: 28487863)
Clin Microbiol Rev. 2004 Oct;17(4):760-9, table of contents. (PMID: 15489346)
J Mol Biol. 2010 Apr 2;397(3):826-34. (PMID: 20109466)
Infect Immun. 2012 Apr;80(4):1479-90. (PMID: 22331427)
Malar J. 2018 Mar 9;17(1):106. (PMID: 29523137)
Mol Biochem Parasitol. 2007 Oct;155(2):103-12. (PMID: 17669514)
Substance Nomenclature:
0 (Antibodies, Protozoan)
0 (Antigens, Protozoan)
0 (Antimalarials)
0 (Drug Combinations)
0 (Immunoglobulin G)
0 (VAR2CSA protein, Plasmodium falciparum)
37338-39-9 (fanasil, pyrimethamine drug combination)
88463U4SM5 (Sulfadoxine)
Z3614QOX8W (Pyrimethamine)
Entry Date(s):
Date Created: 20200816 Date Completed: 20201013 Latest Revision: 20201013
Update Code:
20240105
PubMed Central ID:
PMC7428160
DOI:
10.1371/journal.pone.0237671
PMID:
32797068
Czasopismo naukowe
In high malaria transmission settings, the use of sulfadoxine-pyrimethamine-based intermittent preventive treatment during pregnancy (IPTp-SP) has resulted in decreased antibody (Ab) levels to VAR2CSA. However, information of Ab levels in areas of low or intermediate malaria transmission after long-term implementation of IPTp-SP is still lacking. The present study sought to evaluate antibody prevalence and levels in women at delivery in Etoudi, a peri-urban area in the capital of Yaoundé, Cameroon, that is a relatively low-malaria transmission area. Peripheral plasma samples from 130 pregnant women were collected at delivery and tested for IgG to the full-length recombinant VAR2CSA (FV2) and its most immunogenic subdomain, DBL5. The study was conducted between 2013 and 2015, approximately ten years after implementation of IPTp-SP in Cameroon. About 8.6% of the women attending the clinic had placental malaria (PM). One, two or 3 doses of SP did not impact significantly on either the percentage of women with Ab to FV2 and DBL5 or Ab levels in Ab-positive women compared to women not taking SP. The prevalence of Ab to FV2 and DBL5 was only 36.9% and 36.1%, respectively. Surprisingly, among women who had PM at delivery, only 61.5% and 57.7% had Ab to FV2 and DBL5, respectively, with only 52.9% and 47.1% in PM-positive paucigravidae and 77.7% of multigravidae having Ab to both antigens. These results suggest that long-term implementation of IPTp-SP in a low-malaria transmission area results in few women having Ab to VAR2CSA.
Competing Interests: The authors have declared that no competing interest exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies